Equities analysts expect Sio Gene Therapies Inc. (NASDAQ:SIOX – Get Rating) to announce ($0.24) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sio Gene Therapies’ earnings. Sio Gene Therapies posted earnings per share of ($0.19) in the same quarter last year, which would suggest a negative year over year growth rate of 26.3%. The business is scheduled to announce its next earnings results on Monday, January 1st.
On average, analysts expect that Sio Gene Therapies will report full-year earnings of ($1.04) per share for the current financial year. For the next year, analysts anticipate that the company will report earnings of ($1.18) per share. Zacks’ EPS calculations are a mean average based on a survey of research analysts that that provide coverage for Sio Gene Therapies.
Sio Gene Therapies (NASDAQ:SIOX – Get Rating) last posted its quarterly earnings data on Friday, February 11th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.09).
Shares of NASDAQ:SIOX remained flat at $$0.29 during trading on Friday. 416,836 shares of the stock were exchanged. The firm’s fifty day moving average is $0.59 and its two-hundred day moving average is $1.09. The firm has a market cap of $21.15 million and a PE ratio of -0.34. Sio Gene Therapies has a twelve month low of $0.27 and a twelve month high of $2.95.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SIOX. Two Sigma Securities LLC purchased a new position in shares of Sio Gene Therapies in the third quarter valued at $28,000. Marshall Wace LLP purchased a new position in shares of Sio Gene Therapies in the third quarter valued at $103,000. Morgan Stanley boosted its stake in shares of Sio Gene Therapies by 136.5% in the third quarter. Morgan Stanley now owns 68,383 shares of the company’s stock valued at $149,000 after purchasing an additional 39,471 shares during the period. Franklin Resources Inc. purchased a new position in shares of Sio Gene Therapies in the third quarter valued at $179,000. Finally, State Street Corp raised its holdings in Sio Gene Therapies by 42.9% in the fourth quarter. State Street Corp now owns 157,200 shares of the company’s stock valued at $203,000 after acquiring an additional 47,200 shares in the last quarter.
Sio Gene Therapies Company Profile (Get Rating)
Sio Gene Therapies, Inc, a clinical-stage company, focuses on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases. The company develops AXO-Lenti-PD, in vivo lentiviral gene therapy, which is in Phase II clinical trials for the treatment of Parkinson's disease; AXO-AAV-GM1, an investigational gene therapy , which is in Phase I/II clinical trials for the treatment of GM1 gangliosidosis; and AXO-AAV-GM2, an investigational gene therapy, which is in Phase I/II clinical trials for the treatment of GM2 gangliosidosis.
- Get a free copy of the StockNews.com research report on Sio Gene Therapies (SIOX)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sio Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sio Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.